Guardant Health price target raised to $40 from $32 at UBS

UBS analyst Dan Leonard raised the firm’s price target on Guardant Health to $40 from $32 and keeps a Buy rating on the shares. Guardant Health’s leadership position in the still nascent tumor profiling market coupled with credible opportunities in the larger cancer screening and residual disease monitoring markets supports an industry-leading sales growth rate and catalyst path, the analyst tells investors in a research note.